🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🤔 How to choose a 1st line therapy in mCRPC patients nowadays ? 🚨 ➤ Some excellent suggestions from Christopher Sweeney, MBBS at Advanced Prostate Cancer Consensus Conference OncoAlert #APCCC24

#APCCC24 L.G. Horvath - Incidence of gynecomastia, generally ranging from 36-55% Across the board for bicalutamide, enzalutamide, darolutamide, and apalutamide UroToday.com

Important reminder from Karim Fizazi about bone protection in mCRPC. #APCCC24

For mCRPC patients who began first-line treatment with ADT+ARPI+docetaxel, the primary subsequent option is 177Lu-PSMA, whether DDR alterations are present or not. What considerations guide the transition to 177Lu-PSMA therapy? #APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin

Important session!

"In some low to middle income countries, mobile devices are more reliably accessible than electricity and cleanwater" Stacy Loeb, MD at #APCCC24 highlighting the opportunity that exists to connect with people in LMIC with #prostatecancer

Key takeaways from Stacy Loeb, MD on social media & AI use: 🔸️holds great promise for LMICs 🔸️need to ensure accuracy, comprehensibility & equity 🔸️good access to devices exists 🔸️studies show clinical benefits 🔸️can scale at low cost 🔸️representation important #APCCC24

💫🌟 Day 2️⃣ at #APCCC24 was filled with groundbreaking insights in prostate cancer treatment! Here are the key takeaways: #APCCC24 Advanced Prostate Cancer Consensus Conference OncoAlert silke gillessen aurelius omlin 🔬 Dr. Alicia Morgans & Dr. Daniel George highlighted the expansive IRONMAN project, revealing

Amazing lecture on the prevalence & actionability of germline mutations in #prostatecancer as well as the importance of discussing family history with patients -Heather H. Cheng #apccc24

🚨 Excellent talk on germline testing in PC by Heather H. Cheng🚨 ✅ It matters for patients AND families ✅ Germline alt. are FREQUENT and have consequences for patients 🧬Tumor-only sequencing failed to detect > 20% of pathogenic variants ⚠ Advanced Prostate Cancer Consensus Conference OncoAlert #APCCC24

Fantastic and practical talk from Louise Emmett #APCCC24

Expert panel calls for increased use of SPECT/CT with LuPSMA. Voting currently does not reflect this. #APCCC24

Amazing last session at #APCCC24 on #PSMA for diagnostics & treatment with some of the world's best! 🧩 Patient selection is key 🧩 Role of FDG PET - TBD 🧩 SPECT/CT needed 🧩 Adaptive dosing possible 🧩 Toxicity considerations - delayed, renal, marrow 🧩 Optimal sequencing TBD

And that's a wrap for #APCCC24! An informative and inspiring 4 days with some of the best in #ProstateCancer, all pushing to improve patient outcomes & evidence-based practice. Great science, challenging debates, beautiful backdrop & awesome humans. Advanced Prostate Cancer Consensus Conference

Thanks to Sarah Weller from Movember Australia & Dr Carolyn Mazariego-Jones from the COSA PROMs group for co-facilitating a thought-provoking workshop identifying priorities, challenges & opportunities for collaborative PROM/PREMs implementation to enhance #cancercare jn Australia #COSA24

Great to see the work done by COSA and ASCO in improving equity in cancer care, particularly with access to clinical trials #cosa24

Who is listening and responding to health inequities for our Indigenous people? Powerful call to action from Gail Garvey #COSA24

Tiffany Li #cosa24 When assessing #chemotherapy induced peripheral #neuropathy the most valid and responsive tools are #PROMs

This is such a fantastic tool!

The Australian Real World Cancer Evidence Network hopes to advance #PROM & #PREM use across Aus at an individual and systems level. Check out the latest episode of Talking HealthTech where myself, Bogda Koczwara 🌻🌻🌻 and Cancer Australia (Cindy Toms) discuss this project. Movember Australia